FAQS

CERVIRON® is recommended for women with acute or chronic vulvovaginitis, cervical erosion, post-operative recovery after gynaecological surgery and as an adjuvant supportive treatment to complement antibiotic or antifungal treatment regimens, enhancing their effect and contributing to a complete recovery. CERVIRON® helps alleviate vaginal symptoms associated with vulvovaginitis and cervical erosions, restores vaginal pH and normalises vaginal flora.
CERVIRON® is a treatment recommended for acute and chronic vulvovaginitis of atrophic, aerobic, traumatic and infectious etiology, of cervical erosions of traumatic or infectious origin and of bleedings caused by them, in the postoperative recovery after gynaecological surgeries, for restoration of pH and normal vaginal flora, as well as an adjuvant in the treatment with antibiotics or antifungals.

The ovule melts in the vaginal mucosa forming a cream that ensures even dispersion of the substances contained and acts as a protective barrier with astringent effect, favouring the reepithelialisation of damaged tissue and the restoration of the initial colpo-ecosystem without affecting the Döderlein bacilli. The components responsible for the therapeutic effect are bismuth subgallate and hydrolysed vegetable collagen.

CERVIRON® is compatible as a supportive adjunct to antibiotic or antifungal treatment schemes, enhancing their effect and supporting full recovery.
CERVIRON® one ovule is administered intravaginally, preferably in the evening before going to bed or according to the medical prescription. The use of ovules begins on the first day after menstruation. The duration of administration is 10 or 15 days per month, or according to the doctor’s instructions. The effects can appear after the first month of treatment. Usage can be repeated for several months until healing, or to consolidate and maintain the favourable effects obtained.

Using topical products for a long time may cause local irritation and sensitization. If side effects occur, stop treatment and contact your doctor or pharmacist. Any serious incident that occurred in relation to the medical device must be reported to the manufacturer and the competent authority of the Member State where the patient is established.

top